AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11198486 — intervention group
Group type: COMPARATOR
Intervention: Healthy control patients
Number of subjects: 44
Study 9011463 — intervention group
Group type: EXPERIMENTAL
Intervention: MS patients with increased intestinal permeability
Number of subjects: 20
Study 9011463 — intervention group
Group type: EXPERIMENTAL
Intervention: CD45RO expression on CD20+ B cells in MS patients
Number of subjects: 20
Study 9011463 — intervention group
Group type: EXPERIMENTAL
Intervention: Coincident MS and UC patients
Number of subjects: 20
Study 9011463 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 9011463 — intervention group
Group type: COMPARATOR
Intervention: Patients with Crohn's disease
Number of subjects: 20
Study 1504890 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarosan (acaricidal cleaner)
Number of subjects: 20
Study 1504890 — intervention group
Group type: COMPARATOR
Intervention: Intensive cleaning (control)
Number of subjects: 20
Study 6319338 — intervention group
Group type: EXPERIMENTAL
Intervention: VCA-IgA
Number of subjects: 200
Study 6319338 — intervention group
Group type: EXPERIMENTAL
Intervention: VCA-IgG
Number of subjects: 200
Study 6319338 — intervention group
Group type: EXPERIMENTAL
Intervention: EA-IgA
Number of subjects: 200
Study 6319338 — intervention group
Group type: EXPERIMENTAL
Intervention: EA-IgG
Number of subjects: 200
Study 6319338 — intervention group
Group type: COMPARATOR
Intervention: EA-IgA, EA-IgG, VCA-IgG
Number of subjects: 200
Study 6319338 — intervention group
Group type: EXPERIMENTAL
Intervention: VCA-IgA, VCA-IgG, EA-IgA, EA-IgG
Number of subjects: 200
Study 31098832 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mL of 6% CHO mouth rinse
Number of subjects: 12
Study 31098832 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) mouth rinse
Number of subjects: 12
Study 31098832 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO mouth rinse
Number of subjects: 12
Study 27128776 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar laparoscopic loop and bipolar morcellator
Number of subjects: 124
Study 27128776 — intervention group
Group type: COMPARATOR
Intervention: Monopolar hook and conventional mechanical morcellator
Number of subjects: 124
Study 26586448 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Number of subjects: 379
Study 26586448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379
Study 24833043 — intervention group
Group type: EXPERIMENTAL
Intervention: bilastine (20 mg)
Number of subjects: 12
Study 24833043 — intervention group
Group type: COMPARATOR
Intervention: hydroxyzine (25 mg)
Number of subjects: 12
Study 22252289 — intervention group
Group type: EXPERIMENTAL
Intervention: Coroflex(®) Please stents (B. Braun, Melsungen, Germany)
Number of subjects: 95
Study 19569964 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02A vaccine
Number of subjects: 2022
Study 17848496 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention-to-treat (ITT) analysis
Number of subjects: 403
Study 17848496 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ITT
Number of subjects: 403
Study 17848496 — intervention group
Group type: EXPERIMENTAL
Intervention: Violation of ITT
Number of subjects: 403
Study 17848496 — intervention group
Group type: EXPERIMENTAL
Intervention: Unclear ITT approach
Number of subjects: 403
Study 17848496 — intervention group
Group type: EXPERIMENTAL
Intervention: Missing data
Number of subjects: 403
Study 17848496 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss to follow-up
Number of subjects: 403
Study 15165613 — intervention group
Group type: EXPERIMENTAL
Intervention: L-ornithine alpha-ketoglutarate (OKG) 10 g/d for 12 weeks
Number of subjects: 46
Study 15165613 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isonitrogenous)
Number of subjects: 46
Study 11265953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT)
Number of subjects: 278
Study 11265953 — intervention group
Group type: COMPARATOR
Intervention: Support groups
Number of subjects: 278
Study 11265953 — intervention group
Group type: COMPARATOR
Intervention: Natural course
Number of subjects: 278
Study 9597564 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorzoxazone 250 mg
Number of subjects: 16
Study 9597564 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorzoxazone 750 mg
Number of subjects: 16
Study 7905550 — intervention group
Group type: EXPERIMENTAL
Intervention: More-effective treatments (6 or more cycles of cyclophosphamide, methotrexate, fluorouracil and prednisone; with or without tamoxifen, or tamoxifen and prednisone alone)
Number of subjects: 2108
Study 7905550 — intervention group
Group type: COMPARATOR
Intervention: Less-effective treatments (no treatment or a single cycle of chemotherapy)
Number of subjects: 2108
Study 3266449 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.01 mg/kg, intravenous)
Number of subjects: 50
Study 3266449 — intervention group
Group type: COMPARATOR
Intervention: Induction of neuroleptanalgesia
Number of subjects: 50
Study 31982148 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg SC every 4 weeks
Number of subjects: 0
Study 31982148 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg SC every 4 weeks
Number of subjects: 0
Study 31570429 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel treatment in variant carriers (ANO7 rs77559646)
Number of subjects: 0
Study 28538831 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Manual Therapy (LMT)
Number of subjects: 20
Study 28538831 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 20
Study 24871960 — intervention group
Group type: EXPERIMENTAL
Intervention: Website training on safety with dogs for 2 weeks
Number of subjects: 68
Study 24871960 — intervention group
Group type: COMPARATOR
Intervention: Control website on transportation safety for 2 weeks
Number of subjects: 68
Study 23379785 — intervention group
Group type: EXPERIMENTAL
Intervention: High-bolus-dose tirofiban
Number of subjects: 383
Study 23379785 — intervention group
Group type: COMPARATOR
Intervention: Abciximab
Number of subjects: 383
Study 21234549 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3783 (1-40 mg oral doses)
Number of subjects: 9
Study 19899372 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized mammotest every 2 years
Number of subjects: 0
Study 18293707 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine (LCZ) 5 mg p.o.
Number of subjects: 18
Study 18293707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15031430 — intervention group
Group type: EXPERIMENTAL
Intervention: Early imaging (MR or CT)
Number of subjects: 782
Study 15031430 — intervention group
Group type: COMPARATOR
Intervention: Delayed selective imaging
Number of subjects: 782
Study 12418583 — intervention group
Group type: EXPERIMENTAL
Intervention: telithromycin 800 mg once daily (qd) for 5 days
Number of subjects: 325
Study 12418583 — intervention group
Group type: COMPARATOR
Intervention: amoxicillin/clavulanate 500/125 mg three times daily (tid) for 10 days
Number of subjects: 325
Study 10080588 — intervention group
Group type: EXPERIMENTAL
Intervention: BR96‐doxorubicin conjugate 700 mg/m2 IV over 24 hours
Number of subjects: 23
Study 10080588 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 60 mg/m2 every 3 weeks
Number of subjects: 23
Study 10080588 — intervention group
Group type: EXPERIMENTAL
Intervention: BR96‐doxorubicin conjugate
Number of subjects: 23
Study 10080588 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 23
Study 7549121 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cells Collection (PBSCC)
Number of subjects: 65
Study 7549121 — intervention group
Group type: COMPARATOR
Intervention: Bone Marrow Collection (BMC)
Number of subjects: 65
Study 7549121 — intervention group
Group type: EXPERIMENTAL
Intervention: PBSCC with femoral catheter
Number of subjects: 65
Study 7549121 — intervention group
Group type: EXPERIMENTAL
Intervention: PBSCC without femoral catheter
Number of subjects: 65
Study 2256010 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician's usual advice to stop smoking + signed agreement + health visitor visits + letters of encouragement
Number of subjects: 2854
Study 2256010 — intervention group
Group type: COMPARATOR
Intervention: Advice only
Number of subjects: 2854
Study 2256010 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice supplemented by signed agreement
Number of subjects: 2854
Study 2256010 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice supplemented by letters of encouragement
Number of subjects: 2854
Study 2256010 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice supplemented by signed agreement and letters of encouragement
Number of subjects: 2854
Study 6998872 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg spironolactone
Number of subjects: 45
Study 6998872 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg spironolactone
Number of subjects: 45
Study 6998872 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg spironolactone
Number of subjects: 45
Study 6998872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 29722252 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.07g/kg/d)
Number of subjects: 18
Study 29722252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 28591833 — intervention group
Group type: EXPERIMENTAL
Intervention: Follitropin epsilon (25, 75, 150, and 300 IU)
Number of subjects: 76
Study 28591833 — intervention group
Group type: EXPERIMENTAL
Intervention: Follitropin epsilon (75 IU or 150 IU once daily, or 150 IU every other day)
Number of subjects: 76
Study 28591833 — intervention group
Group type: COMPARATOR
Intervention: 150 IU Gonal-f
Number of subjects: 76
Study 28591833 — intervention group
Group type: COMPARATOR
Intervention: 150 IU Bravelle
Number of subjects: 76
Study 28591833 — intervention group
Group type: EXPERIMENTAL
Intervention: Follitropin epsilon (150 IU)
Number of subjects: 76
Study 28591833 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of follitropin epsilon
Number of subjects: 76
Study 25692781 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 2889
Study 25692781 — intervention group
Group type: COMPARATOR
Intervention: Diabetes mellitus support and education (DSE)
Number of subjects: 2889
Study 23525779 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based osteoarthritis self-management support intervention
Number of subjects: 515
Study 23525779 — intervention group
Group type: COMPARATOR
Intervention: Health education (HE)
Number of subjects: 515
Study 23525779 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 515
Study 21343332 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard intervention (nine postcards sent over 12 months)
Number of subjects: 2300
Study 21343332 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (control group)
Number of subjects: 2300
Study 19563497 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous etanercept therapy (25 mg SC BIW throughout 54 weeks)
Number of subjects: 711
Study 19563497 — intervention group
Group type: EXPERIMENTAL
Intervention: Paused etanercept therapy (50 mg SC BIW for up to 12 weeks, then 25 mg BIW upon retreatment)
Number of subjects: 711
Study 19563497 — intervention group
Group type: COMPARATOR
Intervention: Continuous etanercept therapy
Number of subjects: 711
Study 19563497 — intervention group
Group type: COMPARATOR
Intervention: Paused etanercept therapy
Number of subjects: 711
Study 19563497 — intervention group
Group type: EXPERIMENTAL
Intervention: Both continuous and paused etanercept treatment
Number of subjects: 711
Study 17689601 — intervention group
Group type: EXPERIMENTAL
Intervention: PP-CVD course (2-month course on Primary Prevention of Adult Cardiovascular Disease)
Number of subjects: 280
Study 17689601 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 280
Study 15390313 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ciprofloxacin after delayed intensification (DI) courses
Number of subjects: 69
Study 15390313 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (no prophylactic ciprofloxacin)
Number of subjects: 69
Study 11737129 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser
Number of subjects: 15
Study 11737129 — intervention group
Group type: COMPARATOR
Intervention: Long-pulsed Nd:YAG laser
Number of subjects: 15
Study 9298132 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary excretion of 5-S-cysteinyldopa (5-S-CD)
Number of subjects: 50
Study 9298132 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary excretion of 5-S-cysteinyldopa (5-S-CD) > 1,000 micrograms/day
Number of subjects: 50
Study 9298132 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary excretion of 5-S-cysteinyldopa (5-S-CD) > 10,000 micrograms/day
Number of subjects: 50
Study 9298132 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary excretion of 5-S-cysteinyldopa (5-S-CD) > 40,000 micrograms/day
Number of subjects: 50
Study 8370861 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic (EMG) biofeedback
Number of subjects: 78
Study 8370861 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 78
Study 8370861 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative medical treatment
Number of subjects: 78
Study 2873379 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (5-10 mg iv immediately, followed by 100 mg/day orally for 7 days)
Number of subjects: 16027
Study 2873379 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 16027
Study 30637862 — intervention group
Group type: EXPERIMENTAL
Intervention: Active sTMS
Number of subjects: 0
Study 30637862 — intervention group
Group type: COMPARATOR
Intervention: Sham sTMS
Number of subjects: 0
Study 28616715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of bevacizumab without anterior chamber paracentesis (group A)
Number of subjects: 90
Study 28616715 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal injection of bevacizumab with anterior chamber paracentesis (group B)
Number of subjects: 90
Study 25573272 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month supplementation with omega 3&6 and antioxidants
Number of subjects: 120
Study 25573272 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 24080992 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid, 4 mg, concurrently with the start of RT and then every six months for a total of 6 infusions (Arm 1)
Number of subjects: 96
Study 24080992 — intervention group
Group type: COMPARATOR
Intervention: Observation (Arm 2)
Number of subjects: 96
Study 21484236 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood induction
Number of subjects: 42
Study 21484236 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood induction
Number of subjects: 42
Study 21484236 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-related mood induction
Number of subjects: 42
Study 21484236 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral mood induction
Number of subjects: 42
Study 21484236 — intervention group
Group type: COMPARATOR
Intervention: Healthy control individuals
Number of subjects: 42
Study 18201783 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 171
Study 18201783 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful cardioversion
Number of subjects: 171
Study 18201783 — intervention group
Group type: COMPARATOR
Intervention: Unsuccessful cardioversion
Number of subjects: 171
Study 17143195 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/day RRR-alpha-tocopherol
Number of subjects: 58
Study 17143195 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/day mixed tocopherols (60% gamma-tocopherol)
Number of subjects: 58
Study 17143195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 15138711 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion etoposide (days 1-6)
Number of subjects: 138
Study 15138711 — intervention group
Group type: COMPARATOR
Intervention: Bolus infusion etoposide (over 10 h on day 7)
Number of subjects: 138
Study 15138711 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose etoposide (schedule-dependent)
Number of subjects: 138
Study 11294082 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (specifics not available)
Number of subjects: 0
Study 11294082 — intervention group
Group type: COMPARATOR
Intervention: Tricyclic antidepressants
Number of subjects: 0
Study 11294082 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0
Study 9039836 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated diet (SAT)
Number of subjects: 9
Study 9039836 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated diet (POLY)
Number of subjects: 9
Study 9039836 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated diet (MONO)
Number of subjects: 9
Study 9039836 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed state
Number of subjects: 9
Study 9039836 — intervention group
Group type: COMPARATOR
Intervention: Unfed state
Number of subjects: 9
Study 8425934 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated malingering group
Number of subjects: 57
Study 8425934 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study 8425934 — intervention group
Group type: EXPERIMENTAL
Intervention: RMT and HRD indicators
Number of subjects: 57
Study 3304790 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix 320 (ioxaglate)
Number of subjects: 0
Study 3304790 — intervention group
Group type: EXPERIMENTAL
Intervention: Niopam 370 (iopamidol)
Number of subjects: 0
Study 3304790 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipaque 350 (iohexol)
Number of subjects: 0
Study 3304790 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 2087150 — intervention group
Group type: EXPERIMENTAL
Intervention: GRF(1-29)NH2 (150 micrograms; i.v.)
Number of subjects: 23
Study 2087150 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline, 1 ml; i.v.)
Number of subjects: 23
Study 240205 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg of lorazepam (orally) as a soporific and premedication
Number of subjects: 48
Study 240205 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of lorazepam (orally) as a soporific and premedication
Number of subjects: 48
Study 240205 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam (both dosages)
Number of subjects: 48
Study 31269050 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (home visits, baby massage, and parenting program)
Number of subjects: 233
Study 31269050 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 233
Study 28689036 — intervention group
Group type: EXPERIMENTAL
Intervention: 3g edetate disodium-based infusion
Number of subjects: 26
Study 28689036 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion of 500mL normal saline and 1.2% dextrose
Number of subjects: 26
Study 25294097 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin (GnRH analogue) (n = 12)
Number of subjects: 22
Study 25294097 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 22
Study 22658289 — intervention group
Group type: EXPERIMENTAL
Intervention: Client change talk (CT) during brief motivational interventions (BMIs)
Number of subjects: 127
Study 22658289 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of ability/desire/need to change
Number of subjects: 127
Study 22658289 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of ability/desire/need not to change
Number of subjects: 127
Study 22658289 — intervention group
Group type: EXPERIMENTAL
Intervention: Average strength of ability/desire/need
Number of subjects: 127
Study 22658289 — intervention group
Group type: EXPERIMENTAL
Intervention: CT length
Number of subjects: 127
Study 20957391 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based treatment (GT)
Number of subjects: 61
Study 20957391 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual treatment (IT)
Number of subjects: 61
Study 20957391 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention programme (nutrition and exercise counselling)
Number of subjects: 61
Study 20957391 — intervention group
Group type: COMPARATOR
Intervention: Normal weight children (control group)
Number of subjects: 61
Study 22253980 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum (BC) supplementation (60 g/day)
Number of subjects: 30
Study 22253980 — intervention group
Group type: COMPARATOR
Intervention: Whey protein (WP)
Number of subjects: 30
Study 22253980 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 30
Study 17427144 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza split vaccine vaccination
Number of subjects: 0
Study 14969650 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 62
Study 14969650 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime NPH insulin
Number of subjects: 62
Study 10932334 — intervention group
Group type: EXPERIMENTAL
Intervention: Brainmachine programs
Number of subjects: 0
Study 9301444 — intervention group
Group type: COMPARATOR
Intervention: Control group (79 patients)
Number of subjects: 199
Study 9301444 — intervention group
Group type: EXPERIMENTAL
Intervention: HEP group (72 patients)
Number of subjects: 199
Study 9301444 — intervention group
Group type: EXPERIMENTAL
Intervention: HEP/5-FU group (84 patients)
Number of subjects: 199
Study 8365296 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin (7 mg/L)
Number of subjects: 7
Study 8365296 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn dust extract (0.08 ml/kg)
Number of subjects: 7
Study 8365296 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean dust extract (0.08 ml/kg)
Number of subjects: 7
Study 8365296 — intervention group
Group type: COMPARATOR
Intervention: HBSS (control)
Number of subjects: 7
Study 3484828 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 192
Study 3484828 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold stimulation
Number of subjects: 192